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Background: GD1-DS3 is an integrated assessment of type 1 Gaucher disease (GD1) burden based on bone,
hematologic and visceral domains. We investigated this disease severity scoring system (DS3) methodology for
initial assessment, long-term follow-up and evaluation of treatment responses.
Methods: We enrolled 133 treated adult GD1 patients. Baseline DS3 scores were calculated near the initial
treatment date and patients stratified by severity as marked (DS3 6.00-19.00), moderate (DS3 3.00-5.99), mild
(DS3 < 3.00). Follow-up scores were calculated annually. Minimal clinically important improvement (MCII), is
defined as ΔDS3 of -3.1.
Results: Patient characteristics: N370S was the most common allele (118 patients had at least one), 52 were N370S/N370S
(48/52 were Ashkenazi Jews), N370S/L444P was the most common genotype among non-Jews. Median age of treatment:
45 years; median follow-up: 14 years. Baseline DS3 scores: Patients with marked disease (N = 58; median 7.84) were least
likely to be N370S homozygous (19 %) and most likely to have had splenectomy (53 %), early age at diagnosis (median
18 years) and major pre-treatment bone pathology (76 %). Among patients with moderate disease (N = 53; median 4.33),
49 % were N370S/N370S, 15.1 % had splenectomy and 17 % had major bone disease. Median age at diagnosis: 32 years.
No patient with mild disease (N = 22; median 2.4) had splenectomy or major skeletal disease. Median age at diagnosis:
40 years. 68 % were N370S homozygous. Response to treatment: Health-state transitions occurred primarily during the
early treatment years. At Year 5, among 48 evaluable patients with marked baseline disease, eight were unchanged in
severity status whereas 40 had MCII of varying degrees with 11 scored as mild. Among 42 evaluable moderate patients,
none worsened, 16 remained moderate and 26 improved to mild. Among 16 evaluable mild patients, 14 remained so
and 2 had DS3 scores in the low moderate range.
Conclusions: DS3 is effective for assessing disease burden in GD1 and for monitoring response. ERT was associated with
MCII in DS3 scores in patients with high severity. Nevertheless, despite better DS3 scores with treatment, GD1 patients
especially those with splenectomy and pre-treatment bone pathology, continued to have bone complications.
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Gaucher disease Type 1 (GD1, OMIM 230800), a reces-
sively inherited, pan-ethnic glycosphingolipid storage
disorder is caused by deficient activity of lysosomal acid
β-glucosidase (glucocerebrosidase, EC3.2.1.45, GCase)
resulting from pathogenic variations in the GCase gene,
GBA1 [1]. GD1 is one of the most prevalent LSDs and
the first to be successfully treated with pharmacologic
recombinant enzyme replacement therapy (ERT) [2].
Disease expression is diverse, subject to genotype, other
genetic modifiers [3, 4] and yet undefined epigenetic
and environmental factors. Untreated patients with
GD1 may be asymptomatic with few signs of disease or
present with combinations of hematologic abnormal-
ities, hepatosplenomegaly, pulmonary involvement and
a spectrum of skeletal pathologies that may cause sub-
stantial morbidity, functional disability and decreased
health-related quality of life [1]. Signs and symptoms
may occur anytime from early childhood to late adult-
hood. The rate and extent of disease progression is
variable, unpredictable, and often independent of the
age at which disease manifestations are first detected
[1]. Significant heterogeneity in rate of improvement in
hematologic, visceral and bone manifestations exists in
treated patients [5, 6]. There are few well-designed
studies that have comprehensively annotated pheno-
typic variation over time or measured treatment effi-
cacy and dose response [7, 8]. Design of such studies
was partly hindered by lack of a validated disease sever-
ity scoring system for GD1 to standardize the monitor-
ing of progression and treatment response and to
define patient cohorts in clinical studies [9]. Early dis-
ease severity scoring indices such as Zimran score [10]
and Hermann score for bone disease [11] primarily em-
phasized advanced and irreversible disease manifesta-
tions. These scores also had limited sensitivity for
annotating changes observed over time in untreated
patients with slow progression or in treated patients
with irreversible manifestations. A newer system, Gaucher
Disease Severity Score Index–Type 1 (GAU-SSI-1), is
complex and requires specialized technology [12]. Other
models for monitoring treatment response focused on
composite achievement of therapeutic goals that are
assigned equal weight without attention to relative clinical
import [5].
A disease severity scoring system (DS3) is a method of
expressing an integrated assessment of disease burden. It
may be used to monitor patient status, determine end-
points in clinical studies, classify disease phenotypes and
compare patients with the same disease. Although often
called ‘disease severity indices’, DS3s may also include
measures of disease activity and organ damage. They are
usually structured as a group of domains (often accord-
ing to organ system) populated with non-redundantitems that are valid, reliable, use feasible and standard-
ized methods of assessment, and are variably weighted
based on associated morbidity and mortality [13]. In
2010, Weinreb et al. reported preliminary testing for val-
idity, reliability and feasibility of a DS3 for adult patients
with GD1 [14]. When 20 patient profiles from the Inter-
national Collaborative Gaucher Group (ICGG) Gaucher
Registry [15] were independently evaluated and scored
by 12 expert GD1 physicians, the GD1-DS3 correlated
very well with a “gold standard” clinical global impres-
sion scale. An additional panel of 23 physicians with
GD1 expertise evaluated the DS3 instrument for reli-
ability, feasibility and construct, criterion and content
validity. Inter-rater reliability was high (0.97, Cohen’s
kappa). The feasibility and content validity indices
were also high (0.95 and 0.96, respectively) [14]. How-
ever, expanded testing in a more diverse population
including splenectomized patients has not been com-
pleted. Here, we further investigate the DS3 score as a
tool for initial assessment and evaluation of treatment
responses in GD1 patients within a consortium of five
geographically separated North American GD treat-
ment centers.
Methods
Patient population
Eligibility criteria included men and women with
GD1 ≥ 18 years old at time of recruitment, regardless
of race, ethnicity or treatment status. Subjects who
started treatment as children were eligible, but data
entry was restricted to dates after the 18th birthday.
Diagnosis of GD was confirmed by leukocyte or skin
fibroblast acid β-glucosidase deficiency and/or DNA
genotype analysis. Eligibility was also contingent on
enrollment in the ICGG Registry. Neuronopathic GD
(GD3) was ruled out based on combinations of per-
sonal and family history, physical examination, and
genotype analysis.
Patients were recruited at University Research Founda-
tion for Lysosomal Storage Diseases, Coral Springs, Florida;
University of Pittsburgh, Pittsburgh, Pennsylvania; Tower
Cancer Research Foundation, Beverly Hills, California;
Emory University, Atlanta, Georgia; and Mount Sinai
Hospital, Toronto, Canada. All participating patients
who were alive prior to the inception of the DS3 study
signed separate informed consents to participate in the
DS3 Severity Score Study and the ICGG Registry using
forms approved by the respective institutional review
boards. Data from 13 patients who died prior to 2010
were included based on previously signed ICGG Regis-
try consent forms. An ICGG-independent data center
calculated the DS3 scores and collated the phenotypic
information. The DS3 Severity Score Study is regis-
tered on Clinicaltrials.gov (NCT01136304).
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Genotypes were reported by the participating investiga-
tors. In most instances, genotypes were determined by
PCR specific oligonucleotide screening for common mu-
tations prevalent in North America (e.g., N370S, L444P,
84GG, IVS2 + 1, R496H, V394L). Samples from some
patients with unidentified alleles were referred to
either the ICGG Registry Genotyping Service at the
laboratory of H. Ronald Scott, MD, PhD at the Univer-
sity of Washington, Seattle, WA, USA or the labora-
tory of Francis Choy, Victoria, BC, Canada, for whole
gene sequencing.
Gaucher disease severity scoring
DS3 severity scoring was performed retrospectively
based on data entries in the ICGG Registry database
supplemented by the study DS3 database according to
instructions in Fig. 1 and evaluated per instructions in
Table 1. Because of irreversible bone and joint damage
and frequent concurrent causes for musculoskeletal pain
especially in older GD1 patients with Registry data en-
tered by multiple, variably experienced observers over
long periods of time, we suspect that the instruction in
Table 1 to restrict evaluation of bone pain to GD-
specific etiologies was often not accomplished in this
retrospective study and possibly unrealistic even inFig. 1 Gaucher Disease Type 1 Severity Scoring System (GD-DS3)prospective studies and clinical trials. Disease severity
states were originally defined [14] as:
 Severe (DS3 9.00-19.00)
 Marked (DS3 6.00-8.99)
 Moderate (DS3 3.00-5.99)
 Mild (DS3 < 3.00)
In Weinreb et al. [14], no test patient had a DS3 score
greater than 12.0. Of five patients with DS3 9.0-12.0,
three were classified by the panel of 12 GD experts as
having “severe” disease and two were evaluated as having
“marked” disease. Comparable variation in the clinical
global expression “gold standard” scale was not observed
for the marked, moderate or mild categories suggesting
that a clinical distinction between marked and severe
disease may be unclear. For this reason, and because
only 15 of our study patients had DS3 scores ≥ 9.00 (and
only 6 greater than 9.33), we decided to conflate the
“marked” and “severe” categories into one “marked” dis-
ease state defined as DS3 9.00-19.00.
In reporting treatment outcomes, the minimal clinically
important difference (MCID) is often more meaningful
than the minimal detectable, statistically significant differ-
ence [16]. MCID is the smallest change that a patient or a
clinician would identify as sufficiently important so as to
Table 1 Gaucher disease type 1 DS3 scoring
General instructions
1. Record date of assessment
2. For each assessment, determine the GD1-DS3 score of the patient at the time of evaluation (See notes below
regarding specific assessments).
a. If current data are not available for all assessments when the DS3 score is calculated, data from previous
evaluations may be used if the patient’s overall clinical status has remained stable and assessments (bone
and visceral imaging, hematological) were collected within 12-24 months before the current date:
b. If bone marrow infiltration and/or bone mineral density data are not available at the time of assessment or
from previous evaluations, the DS3 has been optimized to be accurate and consistent without these
parameters.
c. All other assessment scores within the time frames described above are required.
DS3 score calculation
1. First calculate the average Disease Domain Scores by adding the assessment scores for each domain (bone,
hematological, visceral) and dividing by the number of assessment scores completed. Do not include
assessments that were marked “not available” (NA)
2. The total GD1-DS3 score is the sum of the three Disease Domain Scores.
Maximum possible DS3 score
1. The maximum possible DS3 score is 19.
2. In initial validation testing using 20 patient cases scored at 2 different time points, no patient received a
score higher than 13 and scores above 9 correlated with an expert assessment of “severe disease.”
Interpretation of GD1-DS3 scores
0-3 Borderline to mild disease
3-6 Moderate disease
6-9 Marked disease
>9 Severe disease
Notes regarding specific assessments
1. Lytic lesions, AVN or pathologic fracture “present” means any new occurrence in the past 12 months
2. Bone marrow infiltration may be reported either semi-quantitatively (BMB score) or qualitatively (mild, moderate,
marked to severe
3. For bleeding, an assessment of moderate (no transfusions) or severe (transfusion needed) should be based
on bleeding considered by the assessor to be related to GD, whether due to low platelet count, other
hemostatic disorders or vascular disease such as portal hypertension
4. Assessment of bone pain should be based on severity in the absence of analgesics and should consider only
pain resulting from GD rather than pain attributable to other concurrent musculoskeletal diseases.
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may be determined by distribution based (statistical)
methods, by patient-oriented anchor methods, or by ex-
pert based nominal group technique (Delphi) methods.
There is no consensus on which method is best [17]. The
MCID for DS3 was determined by Delphi method as de-
scribed in Weinreb et al. [14]. Because no patient in this
study met the DS3 MCID criterion for clinical deterior-
ation, in this report, we refer solely to minimal clinically
important improvement (MCII).
Eligibility for the study was not restricted by treat-
ment. 132/133 enrolled patients initially received ERT.
One patient (baseline DS3 5.53) was treated solely with
miglustat for three follow up years. Because scientific
questions related to untreated patients primarily concern
natural rather than modified evolution of disease, wechose to defer analysis of untreated patients to a later
study. Baseline DS3 scores were calculated just prior to
or at the time of initiation of treatment. Follow-up
scores were calculated annually with a ±3 month win-
dow. Registry data entry usually post-dated the occur-
rence of bone complications such as avascular necrosis
(AVN) and fractures. Retrospectively, we were unable to
correlate timing of bone events with acute symptoms
such as bone pain. In routine clinical practice, MRI
evaluation of bone marrow infiltration and measurement
of bone mineral density are rarely performed annually.
Because the calculation of DS3 scores is sensitive to
missing data for these parameters, some entries for bone
marrow infiltration and bone mineral density DS3 com-
ponent scores were imputed as unchanged when data
for the preceding and subsequent year were identical.
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computed without the missing parameters as described
in Table 1.
Statistical analyses
Two-tailed t-test was used for comparing the mean of
continuous outcomes between two groups. Fisher’s exact
test was used to check the independence among mul-
tiple groups in contingency tables. The significance test
for correlations was the t-test from corresponding sim-
ple linear regressions. Disease progression among groups
was compared using Kaplan-Meier survival estimates.
The equivalence of survival curves among difference
groups was examined using the log-rank test. All the
analyses were performed in R, version 3.0.3 (The R Pro-
ject for Statistical Computing).
Results
Data quality and completeness
Due to our ability to supplement ICGG Registry data with
primary source data at the study sites, missing data was
less problematical than we anticipated. The demographic
and pre-treatment characteristics data sets were essentially
complete as shown in the relevant tables below. Informa-
tion about ethnicity and GBA1 genotype was unavailable
for 8 and 6 of the 133 treated study patients.
Data needed to calculate annual DS3 scores was less
easy to recover although often sufficient to allow imput-
ation. Data was imputed for 465 of 1415 possible bone
marrow infiltration entry lines (32.9 %), for 30.2 % of
DEXA BMD entries, for 26.9 % of spleen volume entries
and for 42.6 % of liver volume entries. The difference
between liver and spleen is attributed to patients with a
history of splenectomy. The imputation rate for bone
pain was 5.8 %, for major bone lesions, 2.6 %, and ≤ 1.0
% for bone crises, anemia, thrombocytopenia, clinical
bleeding and pulmonary involvement. The amount of
missing data that could not be imputed was less than 1.0
% for all DS3 components except bone marrow infiltration
(4.4 %) and DEXA BMD (31.0 %). Non-imputable, missing
DEXA data was largely from the 1990’s and early 2000’s
when BMD measurement had not yet been included in
the recommended evaluations for GD1. We believe that
missing data does not significantly impact the validity of
the results we herein report.
Patient enrollment and demographics
One hundred seventy three patients were recruited.
Seven patients were excluded because data was insuf-
ficient to calculate baseline DS3 scores and relevant
medical records were not available for review. Of 166 in-
cluded patients, 33 were untreated. 133 patients started
either ERT (N = 132) or miglustat (N = 1) a median
14 years (range 1-23 years) prior to the analysis date.61 % of the patients were female with a majority of
women at all sites except Los Angeles (Table 2). 68
patients (51.1 %) identified all four grandparents as
Ashkenazi Jews. An additional 13 (9.8 %) claimed partial
Ashkenazi Jewish descent. The majority of patients from
South Florida and Los Angeles were Jewish, whereas
non-Jewish patients constituted the majority in Toronto,
Atlanta and Pittsburgh. The median age (range) at the
time of GD1 diagnosis was 28 (0-85) years. One-third of
the patients were diagnosed before 18 years of age. GD1
treatment was begun at a median age of 45 (6-87) years.
The median interval between diagnosis and treatment
was 17 years. Before 1991 (when alglucerase was ap-
proved in the US), the interval between diagnosis and
treatment was 2 years or less in only 1 of 79 patients
(1.3 %) and greater than 5 years in 74 (93.7 %). Among
54 patients diagnosed in 1991 or later, the median inter-
val between diagnosis and start of treatment was 2 years.
The interval between diagnosis and treatment was
greater than 5 years in only 6 patients (11.1 %).
At initiation of treatment, 55 of 126 patients (44 %) had
one or more co-morbidities that apparently were unre-
lated to GD. Pre-treatment total splenectomy was re-
ported in 39 of 133 patients (29.3 %) with little inter-site
variation. The median age at splenectomy was 25 years
(Range: 3-73 years; Interquartile range: 7.5-36 years). Eight
(20.5 %) patients had splenectomy before age 6 years, 5
(12.8 %) between 6 and 18 years and 26 (66.7 %) after age
18 years. Among patients diagnosed prior to 1991, 36 of
79 (45.6 %) had a splenectomy before starting treatment
but only 3 of 54 (5.6 %) diagnosed in 1991 or later (the
ERT era) were splenectomized. 43 of 79 patients diag-
nosed before 1991 (54.4 %) had a history of a major bone
event (AVN, fracture, or lytic lesion) prior to starting treat-
ment compared to 10 of 54 (18.5 %) of those whose year
of diagnosis was 1991 or later. Two of the 10 patients (20
%) diagnosed post-1991 with pre-treatment bone events
had a history of splenectomy compared to 26 of 43 diag-
nosed before 1991 (60.5 %).
Genotypes
Due in part to ethnic differences, substantial variation in
genotype distribution was observed among the investiga-
tive sites (Table 2). N370S homozygosity was especially
prevalent in South Florida and uncommon in Toronto
and Pittsburgh. 88.8 % of the 133 patients had at least
one N370S allele. 48 of 52 N370S homozygous patients
had complete or partial Ashkenazi Jewish ethnicity.
N370S/L444P was the single most common genotype
among non-Jewish patients but was also found in 6 of
86 (8.8 %) Ashkenazi Jewish patients. Two self-identified
non-Jewish patients (N370S/84GG, N370S /IVS2+1) may
have had incorrect or incomplete information about
their ethnic background.
Table 2 Baseline (pre-treatment) characteristics of 133 treated patients with GD1 by investigative site
Total South Florida Toronto Atlanta Los Angeles Pittsburgh
Patients: N 133 61 25 15 24 8
Patients with splenectomy: n (%) 39 (29.3) 17 (27.9) 8 (32.0) 5 (33.3) 5 (20.8) 4 (50.0)
Women: n (%) 81 (61) 36 (59) 18 (72) 10 (66.7) 11 (45.8) 6 (75)
Ethnicity: n (%)
Ashkenazi Jewish 68 (51.1) 45 (73.8) 4 (16.0) 3 (20.0) 15 (62.5) 1 (12.5)
Part Ashkenazi 13 (9.8) 7 (11.5) 1 (4.0) 1 (6.7) 4 (16.7) 0
Non-Jewish 44 (33.1) 9 (14.8) 19 (76.0) 8 (53.3) 2 (8.3) 6 (75.0)
Unknown 8 (6.0) 0 1 (4.0) 3 (20.0) 3 (12.5) 1 (12.5)
Age at diagnosis (y)
Mean (SD) 29.7 (18.8) 34.6 (21.2) 17.0 (19.2) 30.7 (14.1) 32.0 (18.4) 23.4 (19.1)
Age at first treatment (y)
Mean (SD) 44.5 (18.8 52.2 (16.9) 33.5 (19.3) 37.3 (17.2) 43.1 (16.3) 38.5 (19.0)
Years on treatment
Mean (SD) 13.3 (6.1) 13.3 (6.0) 12.0 (5.6) 14.3 (6.4) 12.8 (6.8) 17.0 (4.6)
Current age (y)
Mean (SD) 57.8 (18.4) 65.5 (15.5) 45.5 (18.9) 51.6 (18.8) 55.9 (16.5) 55.5 (19.2)
Genotype: N (%)
N370S/N370S 52 (39.1) 35 (57.4) 3 (12.0) 5 (33.3) 8 (33.3) 1 (12.5)
N370S/L444P 24 (18.1) 8 (13.1) 7 (28.0) 5 (33.3) 2 (8.3) 2 (25.0)
N370S/84GG 7 (5.3) 4 (6.6) 2 (8.0) 0 1 (4.2) 0
N370S/IVS2+1 4 (3.0) 3 (4.9) 0 0 0 1 (12.5)
N370S/other 31 (23.3) 9 (14.8) 10 (40.0) 4 (26.7) 7 (29.2) 1 (12.5)
L444P/other 3 (2.2) 1 (1.6) 1 (4.0) 0 0 1 (12.5)
L444P/L444P 1 (0.75) 0 1 (4.0) 0 0 0
Other/other 5 (3.8) 1 (1.6) 1 (4.0) 1 (6.7) 0 2 (25.0)
Unknown/missing 6 (4.5) 0 0 0 6 (25.0) 0
Baseline DS3 score*
Mean (SD) 5.6 (2.6) 5.6 (2.5) 6.6 (2.9) 4.4 (2.3) 4.8 (2.4) 7.2 (2.0)
*Two-tailed t-test: Toronto v Atlanta: P=0.016; Toronto v California: P=0.020; Pittsburgh v Atlanta: P=0.008; Pittsburgh v California: P=0.016
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served for clinical phenomena that are traditionally invoked
as markers of disease severity (Table 3). Pre-treatment
splenectomy was significantly less common and age at
diagnosis was significantly greater in patients homozygous
for N370S than in the other genotype groups. Additionally,
the lowest percentage of patients with pre-treatment se-
vere bone events was found among homozygous N370S
patients.
Baseline DS3 severity scores
The mean (SD) baseline DS3 severity score for all 133
patients was 5.6 (2.6) with a 5.5 median score (0.4-14.9;
inter-quartile range 3.7-7.5). The mean baseline DS3
scores varied among investigative sites but no site was
significantly different from South Florida (Table 2).Mean DS3 scores were highest at the centers with the
least number of Ashkenazi Jews.
Baseline mean DS3 scores differed by genotype and
were lowest (in the moderate range) among the 52
N370S homozygous patients. Mean DS3 scores were in
the marked severity range for all other known genotype
sub-groups (highest in the other/other category). Pre-
treatment DS3 scores were in the moderate or marked
range in 71.2 % of the N370S homozygous patients, and,
although uncommon, baseline DS3 scores in the mild
range were found for patients with N370S/L444P and
N370S/other genotypes (Table 4). The mean (SD) base-
line DS3 score in 39 patients with a history of pre-
treatment splenectomy was 7.80 (2.05) vs. 4.69 (2.21) in
94 patients with intact spleens (P < 0.0001). Of 53 pa-
tients with “moderate” DS3 severity, 7 had a history of
Table 3 Splenectomy status, mean age at diagnosis, and pre-treatment bone complications (avascular necrosis, fractures, lytic lesions) and
mean baseline DS3 score by genotype categories
Genotype (N) Splenectomy* Pre-treatment* bone events Mean (SD) age at diagnosis (y) Mean (SD) baseline DS3 score
N370S/N370S (52) 6 (11.5 %)€ 12 (23.1 %) 42 (17) 4.33 (2.30)
N370S/L444P (24) 7 (29.2 %)€ 8 (33.3 %) 22 (15)§ 6.08 (2.49)§
N370S/other (42) 19 (45.2 %)€ 25 (59.5 %) 20 (18)§ 6.68 (2.47)§
Other/other (9) 7 (77.8 %)€ 6 (66.7 %) 20 (20)§ 7.17 (2.32)§
Unknown (6) 0 2 (33.3 %) 36 (28) 4.77 (1.57)
*Of 53 patients with pre-treatment bone events, 25 (47.1 %) had intact spleens and 28 (52.9 %) had splenectomies. Of the 12 N370s homozygotes with pre-treatment
bone events, 8 had intact spleens and 4 had splenectomy
€Splenectomy probabilities: Exact test: P = 0.0082, including unknown patients; P = 0.0074, excluding unknown patients
§Two-tailed t-test
Mean baseline DS3 score
Mean age at diagnosis
N370S/N370S v N370S/L444P: P = 0.0041
N370S/N370S v N370S/L444P: P < 0.0001
N370S/N370S v N370S/other: P < 0.0001
N370S/N370S v N370S/other: P < 0.0001
N370S/N370S v other/other: P = 0.0012
N370S/N370S v N370S/other: P = 0.0009
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than 18 years old at the time of splenectomy. Of 58 pa-
tients with “marked” DS3 severity, 31 had a history of
splenectomy of whom 12 (38.7 %) were younger than
18 years when splenectomy was performed. In 53 pa-
tients with a history of pre-treatment severe bone
events, the mean (SD) baseline DS3 score was 7.61
(1.77) vs. 4.29 (2.20) in 76 patients with no such history
(P < 0.0001). Pre-treatment bone history was unknown
in 4 patients. The mean (SD) baseline DS3 score in 45
patients diagnosed with GD1 when younger than
18 years was 6.70 (2.24) vs. 5.04 (2.58) in 88 patients
older than age 18 years (P = 0.0004). For 79 patients whoTable 4 Characteristics of treatment response sub-groups defined b
marked:* 6.00-19.00)
Characteristics Mild (n = 22)
Baseline DS3 (mean (SD)* 2.03 (0.82)
Splenectomy: N (%) 0
Age (y) at diagnosis
Median (Range) 40.5 (1-71)
Age (y) at 1st treatment
Median (Range) 44.5 (9-73)
Genotype**
N370S/N370S (N = 52) 15 (28.8 %)
N370S/L444P (N = 24) 3 (12.5 %)
N370S/other (N = 42) 3 (7.1 %)
Other/Other (N = 9) 0
Unknown (N = 6) 1 (16.7 %)
*DS3 scores >10.0 were found in only 3 patients and no baseline DS3 score exceed
Mild v Moderate: P < 0.0001
§The DS3 score exceeded 4.33 in 7 of the 8 patients
§§20 of 29 patients (69.0 %) with a baseline DS3 ≥ 8.00
**Percentages refer to the genotype categorywere diagnosed earlier than 1991, the mean (SD) base-
line DS3 score was 6.54 (2.44) vs. 4.23 (2.16) for 54 pa-
tients diagnosed with GD1 in 1991 or thereafter (P <
0.0001).
As shown in Table 4, patients were categorized as having
marked, moderate or mild GD1 severity based on pre-
treatment DS3 scores. Patients with marked severity were
much more likely to have a history of splenectomy and a
substantially younger age at GD1 diagnosis than those in
the moderate or mild categories. However, the three
groups differed very little regarding the age at which treat-
ment was initiated. For the entire 133 patient cohort, a
negative correlation exists between age at diagnosis andy baseline DS3 score (mild: 0-0.299, moderate: 3.00-5.99,
Moderate (n = 53) Marked (n = 58
4.43 (0.92) 8.03 (1.49)
8 (15.1)§ 31 (53.4)§§
32.0 (4-85) 18.5 (0-68)
50.0 (6-87) 44.5 (7-69)
26 (50.0 %) 11 (21.2 %)
8 (33.3 %) 13 (54.2 %)
13 (31.0 %) 26 (61.9 %)
2 (22.2 %) 7 (77.8 %)
4 (66.6 %) 1 (16.7 %)
ed 14.9. Mean DS3 score (two-tailed t-test): Marked v Moderate: P < 0.0001;)
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correlation between years from diagnosis to start of ERT
and baseline DS3 score (ρ = 0.34, P < 0.0001). No correl-
ation exists between age at which treatment was begun
and the baseline DS3 score. Within each severity category,
there was no correlation between baseline DS3 score and
either age at diagnosis or age at start of ERT.
Changes in DS3 scores following initiation of ERT or
miglustat
Initially, 57 patients received alglucerase, 73 imiglucerase, 2
velaglucerase, and 1 miglustat. At the most recent follow-
up, no patient was receiving alglucerase. 71 patients were
receiving imiglucerase, 33 velaglucerase, 1 taliglucerase, 6
miglustat, and 6 were on clinical trials with eliglustat tar-
trate. Treatment had been interrupted in 15 patients and,
in one patient, treatment status is unknown. The median
(range) starting ERT dose was approximately 60 (8-60)
units/kg/every 2 weeks (Q2W) and did not vary signifi-
cantly based on the DS3 severity score (Table 5). Regardless
of ERT product, the median (range) ERT dose at the time
of most recent follow-up continued to approximate 45
(10-120) units/kg/Q2W. However, the dose tended to be
somewhat higher in patients categorized as having marked
disease severity based on pre-treatment DS3 score. For
these response analyses, we have assumed that all commer-
cial ERTs are bio-similar in efficacy and are freely inter-
changeable, although that is not yet definitively proven [18].
Responses to treatment were assessed longitudinally
and as transitions between severity health states. Regard-
less of initial severity, significant changes from baseline
DS3 scores occurred primarily during the early years of
treatment. As shown in Fig. 2, among evaluable patients
with initial marked severity disease, the proportion of
patients in this category progressively decreased over
5 years. Most patients transitioned from marked to mod-
erate, but 19 % improved to mild. Among evaluable ini-
tially moderate patients, 49 % were mild after 5 years of
treatment and the others remained moderate. No pa-
tients progressed to marked disease. Most initially mild
patients remained so throughout the 5 years.
Among evaluable patients with initial marked disease, the
percentage of patients with minimal clinically importantTable 5 ERT dosing per baseline DS3 severity score category (marke
last follow up
ERT dose at initiation of treatment (units/kg/Q2W)
DS3 category No. of pts Median Range
Marked 58 60.0 8-60
Moderate 52 52.5 10-60
Mild 22 60.0 10-60
All ERT doses are expressed as units/kg body weight infused every 2 weeks (Q2W). For
is shown. ERT dose calculations are inclusive of all ERT agents. At the time of last follow
ERT, 77 % of the initially moderate severity patients continued to receive ERT, and 82 %improvement (MCII) defined in the original GD1-DS3
manuscript as a -3.1 ΔDS3 from baseline [14] increased
from 34.8 % after 1 year of ERT to 75.5 % after 5 years
(Table 6). MCII occurred in 9 of 22 patients (40.9 %) in the
moderate sub-group in whom pre-treatment DS3 scores
ranged from 4.58-5.93, whereas no patients with baseline
DS3 scores 3.00-4.50 had a MCII. No initially mild patient
achieved MCII as the defined -3.1 Δ exceeds the maximum
2.99 score for this category. After correcting for initial DS3
severity score, there was no definite relationship between
genotype and attained MCII status in patients with marked
and moderate pre-treatment disease. MCII after 5 years of
ERT occurred in 12 of 33 (36 %) of evaluable patients
homozygous for N370S (baseline DS3 score 5.31) and in 32
of 56 (57 %) of evaluable patients with all other genotypes
(baseline DS3 score 6.99). The likelihood of attaining MCII
was minimally dependent on how quickly ERT was begun
after GD1 diagnosis. Among 79 patients diagnosed prior to
1991 (in whom the interval between diagnosis and treat-
ment exceeded 5 years in 74, 26 patients (33 %) had MCII
after 5 years of ERT including 20 of 29 (69 %) with marked
severity disease (DS3 ≥ 6.00). Among 54 patients diagnosed
in 1991 or later (in whom the interval between diagnosis
and treatment was less than 5 years in 48), 22 patients
(41 %) had a MCII after 5 years of ERT including 17 of
21 (81 %) with marked severity disease.
Improvement in aggregate DS3 scores occurred despite
broad ERT dose ranges within each patient sub-group. Re-
gardless of DS3 severity category, the mean initial ERT
dose was approximately 45 units/kg/Q2W compared to
35 units/kg/Q2W after 5 years (Fig. 3) and there were no
significant differences in mean cumulative ERT dose at
years 1, 2 and 5 between patients who had MCII and those
who did not (Table 6). For those patients who attained
MCII after 5 years but not at year 1, the cumulative ERT
dose during year 1 was not substantially lower than in
those patients who improved more rapidly.
Figure 3 shows the longitudinal changes in mean (SD)
DS3 scores for up to 22 years. Despite considerable eva-
luable patient attrition after 10 years, mean DS3 scores
are relatively static after the first 5 years. However, des-
pite the overall favorable impression of response to ERT,
new episodes of skeletal pathology continue to occurd, moderate, mild) when treatment was initiated and at time of
ERT dose at time of last follow-up (units/kg/Q2W)
No. of pts Median Range
47 50.0 15-120
40 30.0 15-90
18 44.0 10-60
patients who were infused at intervals other than Q2W, the equivalent Q2W dose
up (or death), 81 % of the initially marked severity patients continued to receive
of the initially mild severity patients continued to receive ERT
Baseline Year1 Year2 Year5
45.1(18.7)
8 60U/kg/EOW
43.3(21.5)
2 120U/kg/EOW
43.0(22.1)
0 120U/kg/EOW
37.6(19.3)
0 60U/kg/EOW
44.3(16.7)
10 60U/kg/EOW
35.7(16.6)
0 60U/kg/EOW
35.1(18.9)
0 75U/kg/EOW
32.1(17.1)
0 60U/kg/EOW
47.0(16.7)
10 60U/kg/EOW
41.7(20.1)
0 60U/kg/EOW
44.7(17.8)
10 60U/kg/EOW
37.7(16.4)
10 60U/kg/EOW
33%
43%
2%
22% 23%
41%
5%
31%
14%
50%
19%
17%
40%
41%
19%
25%
49%
26% 30%
49%
21%
82
%
18
%
9%
64%
27%
9%
64%
27%
Marked
(N=58)
Moderate
(N=53)
Mild
(N=22)
Fig. 2 Categorical change from baseline DS3 severity status 1, 2, and 5 years after treatment initiated. Purple color indicates patients for whom
data was unavailable for the year evaluated. Mean (SD) ERT doses and range in units/kg body weight/q 2 weeks are shown beneath the pie
charts. Each sub-group includes a few patients in whom treatment was interrupted during an evaluation period and some patients were treated
at very low doses
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especially, but not exclusively, in the patients with the
highest pre-treatment DS3 severity scores. Among the
patients in whom the baseline DS3 score exceeded 6.00,
38 of 58 (65.5 %) had a total of 82 new episodes of eitherTable 6 Cumulative ERT doses (units/kg) after 1, 2, and 5 years for G
scores and treatment outcomes as determined by “minimal clinically
baseline score for evaluable patients with marked and moderate bas
Baseline DS3 severity category Number (%) of patients with clinically signif
Year 1 Year 2
Marked 16/46 (34.8) 19/40 (47.5)
ΔDS3≥ 3.1 16 19
ΔDS3≤ 3.1 30 21
Moderate 6/42 (14.3) 6/39 (15.4)
ΔDS3≥ 3.1 6 6
ΔDS3≤ 3.1 36 33
Mild 2/17 (11.8) 0/16 (0.0)
ΔDS3≥ 2.0 2 0
ΔDS3≤ 2.0 15 16AVN, fracture or appearance of lytic lesions while on
treatment. 19 patients had multiple new bone events.
73.7 % of the 38 patients with new bone events were
splenectomized and 34 (89.5 %) had a pre-treatment his-
tory of AVN, fracture or lytic lesions. 10 patients with aD1 patients with marked, moderate and mild DS3 baseline
important improvement” defined as a decrease of 3.1 from the
eline disease and 2.0 for patients with mild baseline disease
icant change in DS3 score Mean (SD) cumulative ERT dose units/kg
Year 5 Year 1 Year 2 Year 5
37/49 (75.5)
37 991 (447) 2354 (1136) 5681 (2277)
12 1249 (477) 2147 (857) 5163 (1775)
9/44 (20.5)
9 880 (238) 1835 (668) 3770 (1239)
35 1064 (391) 1854 (762) 4809 (2049)
2/16 (12.5)
2 1170 (552) NA 5850 (2758)
14 1131 (450) 2188 (925) 5478 (2493)
Fig. 3 Changes in mean (± SD) DS3 score after initiation of GD1-specific treatment for patients with pre-treatment marked, moderate or mild disease
as defined by baseline DS3 score a Baseline DS3 scores 6.00-14.87; b Baseline DS3 scores 3.00-5.93; c Baseline DS3 scores 0.40-2.93). Among 58 marked
severity patients (baseline DS3 > 6), 38 patients (65.5 %) had a total of 82 new bone events (avascular necrosis, fracture, lytic lesions) while on treatment:
2.16 episodes per affected patient. Among 53 moderate severity patients (baseline DS3 3.00-5.99), 15 patients (28.3 %) had a total of 19 new bone
events, 1.2 episodes per affected patient. Among 22 mild severity patients (baseline DS3 < 2.99), 4 patients (18.2 %) had a total of 4 events,
1.0 episode per affected patient
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new bone events while on treatment. Among the moder-
ate severity patients, 15 of 53 (28.3 %) had a total of 19
new bone events. Unlike the marked severity patients,
the spleen was intact in 93.3 % and 86.7 % had no pre-
treatment record of AVN, fracture or lytic lesions. Sevenpatients with such a history had no severe skeletal com-
plications after initiation of ERT. Despite the disparity in
prevalence of splenectomy and pre-treatment skeletal
disease between the marked and moderate patients, the
nature of post-treatment bone complications was similar
in both sub-groups with fractures accounting for 35-40
Weinreb et al. Orphanet Journal of Rare Diseases  (2015) 10:64 Page 11 of 16% of the total. Among the 22 mild severity patients, 4
(18.2 %) had a total of 4 skeletal events while on ERT.
All had intact spleens, none had a record of pre-
treatment severe skeletal complications and 3 of 4 had
AVN.
As shown in Fig. 4a, a significant difference in bone
event-free survival depended on DS3 severity score
grouping prior to initiation of ERT. Despite ERT, pa-
tients with pre-treatment marked severity demonstrated
a 58 % chance at 10 years and a 70 % chance at 15 yearsFig. 4 Probabilities, based on baseline DS3 severity status (marked, modera
fracture or lytic bone lesion once GD1 treatment is begun [log-rank test fo
episode of avascular necrosis or lytic bone lesion once GD1 treatment is be
groups: P < 0.0001])of a severe bone complication. For moderately affected
patients, the risk at 10 years is 38 % and 50 % at 15 years
and for mild patients, the 10-year probability is 10 %
and the 15-year probability is 40 %, although the latter
figure may be inaccurate due to small patient numbers.
Based on mean (SD) values, no evidence appeared for a
significant difference in ERT dose for the year preceding
the initial post-treatment bone event between patients
with AVN (37.1 [20.8] units/kg/Q2W), lytic lesions
(36.7 [24.1] units/kg/Q2W) or fractures (44.8 [25.7]te or mild), of living free of a a new episode of avascular necrosis,
r the difference among groups: P = 0.0007], b living free of a new
gun (fracture events excluded [log-rank test for the difference among
Weinreb et al. Orphanet Journal of Rare Diseases  (2015) 10:64 Page 12 of 16units/kg/Q2W). However, 11 of 38 (28.9 %) patients
with either post-treatment AVN or osteolysis were re-
ceiving ERT doses less than 20 units/kg/Q2W (3 had
treatment interruptions) for one year prior to the event,
whereas no patient with a post-treatment fracture had
either treatment interruption or a dose less than 20
units/kg/Q2W.
With aging, GD1 patients may have an increased risk
for fracture that is at least partly non-GD dependent,
whereas, in the absence of concurrent known predispos-
ing factors (corticosteroid use, alcoholism, hyperlipid-
emia, collagen vascular disease, malignancy), AVN and
lytic bone lesions are rare in the general adult popula-
tion [19, 20] and most likely directly attributable to GD1
pathophysiology. Among the patients who suffered new
bone events while on ERT, those with AVN (N = 29;
mean [SD] age 47.1 [20.1] years) and lytic lesions (N = 9;
mean age 43.3 [15.3] years) were significantly younger
than those with fractures (N = 19; mean age 65.6 [10.4]
years) (P = 0.0001). However, even when fracture events
are excluded, ERT-treated patients, especially but not
solely those with pre-treatment DS3 scores >6.00, con-
tinue at risk for new episodes of AVN and osteolysis ir-
respective of ERT dose, suggesting that ERT alone is
sometimes insufficient for achieving a complete remis-
sion of all GD1 manifestations (Fig. 4b).
Discussion
The GD1-DS3 was devised to provide physicians and al-
lied health care providers with a useful and easily applic-
able quantitative instrument to complement clinical
judgment when assessing and monitoring adult patients
with GD1 regardless of treatment status. Referring to
the GD1-DS3 as a severity score is somewhat misleading
as severity of an illness is properly defined in terms of
outcomes such as mortality, morbidity, prevention of
end organ damage and reversibility, none of which are
yet known to be forecast by DS3. Rather, the GD1-DS3
is a composite measure of disease burden. However, with
that caveat and in keeping with earlier literature, we will
continue to use “severity” in this discussion.
GD1-DS3 improves upon older scoring systems such
as the Zimran severity score index (SSI) [10] by incorp-
orating current standard recommended methods for
assessing organomegaly, bone marrow infiltration and
bone mineral density. Because published experience with
the GD1-DS3 has been rudimentary, we undertook this
study of a large, heterogeneous GD1 population to fur-
ther investigate the value of DS3 for quantitating extent
of disease and for monitoring response to treatment.
Our results conform to and amplify previous reports ad-
dressing these areas and should encourage broader use
of DS3 scoring when evaluating the status of adult pa-
tients with GD1.Because of the US/Canada multi-site study design, our
patient cohort is representatively diverse in terms of
genotype and ethnicity. Based on demographic and GD1
prevalence estimates, the proportion of Ashkenazi Jews
in our study is that expected for US/Canada and the
genotype distribution is similar to that reported by
ICGG in 2013 for 2335 North American GD patients
(ICGG 2014 annual report). By restricting this analysis
to treated patients only, we assume most N370S homo-
zygous patients with null to mild severity phenotypes are
filtered out so that the results from our patient cohort
should be applicable to GD1 patients worldwide despite
the different genotype profiles. 83 % of our study pa-
tients had pre-treatment DS3 scores in either the moder-
ate or marked severity range.
As hypothesized, DS3 scores were consistent with trad-
itional surrogate indicators of GD1 severity. On average,
scores were significantly higher for genotype groupings
commonly believed to be associated with greater disease
severity (N370S/L444P, N370S/other, other/other) than for
N370S/N370S [21, 22]. A higher than expected average
DS3 score for N370S homozygote patients reflects selec-
tion bias towards clinically more severe phenotypes [23].
The mean DS3 score in 18 N370S homozygotes from the
untreated patients in our patient population excluded
from this analysis (2.16 [1.40]) is significantly lower than
the score of 4.33 (2.30) in the treated patients (P = 0.0004).
Baseline DS3 scores were significantly greater in pa-
tients with a history of pre-treatment splenectomy.
Splenectomy in untreated GD1 patients is known to in-
crease risk for AVN [24], liver fibrosis [25], pulmonary
hypertension [26] and possibly malignancies [27, 28].
With the exception of AVN, none of our patients pre-
sented with these complications prior to inception of
ERT. Our results also confirm previous reports indicat-
ing a dramatic decrease in the need for therapeutic
splenectomy in GD1 patients since the advent of ERT in
1991 [9, 27]. AVN, fractures and osteolytic lesions are
traditional indicators of GD1 severity now used in mod-
eling analyses to define stages of GD1 progression [29].
As anticipated, high baseline DS3 scores were signifi-
cantly associated with a history of pre-treatment severe
bone complications. The cumulative incidence of pre-
treatment bone events from the date of GD1 diagnosis
was 0.14 at ten years and 0.23 at 20 years. This experi-
ence closely conforms to that recently reported in a co-
hort of symptomatic Dutch patients and in the French
GD Registry [29, 30].
When coincident with GD1 signs and symptoms, age at
diagnosis is a commonly invoked surrogate for disease se-
verity and is a component of the Zimran SSI [10]. In 247
French GD1 patients, age at diagnosis ≤15 years was asso-
ciated with an increased risk for bone events [30]. Because
nearly all the DS3 study patients were diagnosed due the
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screening, we postulated that they were likely symptom-
atic at or prior to date of diagnosis and that a younger age
at diagnosis should be associated with a higher pre-
treatment DS3 score. Indeed, baseline DS3 scores were
significantly higher in patients who were diagnosed before
age 18 years than in those diagnosed when older and pa-
tients who were categorized as having marked severity dis-
ease were significantly younger when diagnosed than
those with milder disease scores. However, because age at
diagnosis is not solely dependent on onset of clinical GD1
manifestations but is also subject to non-biological deter-
minants such as diagnostic delay, the correlations between
age of diagnosis and DS3 severity scores were relatively
weak. Although we anticipated a strong direct relationship
between baseline DS3 score and years from diagnosis to
start of treatment, the correlation was also weak although
statistically significant. This confirms repeated observa-
tions that progression in adult GD1 patients is stochastic
rather than linear and, in particular, pre-treatment bone
complications that are heavily responsible for increases in
the DS3 score usually occur infrequently and sporadically
even over 20-25 untreated years [29–31]. In 24 GD1 sib-
ling groups in whom treatment decisions conformed to
relatively uniform guidelines, Amato et al. [32] confirmed
the hypothesis that the age at which ERT is begun is a
rough surrogate for disease severity. We were unable to
demonstrate this relationship in our study because, for
many of our patients, age at start of treatment was primar-
ily dictated by the advent of ERT in 1991 rather than by
proximal GD1 complications. Furthermore, even for those
patients diagnosed after 1991 in whom treatment gener-
ally commenced within 0-2 years of diagnosis, heteroge-
neous criteria for starting ERT thwarted our ability to
demonstrate a relationship between age at initiation of
ERT and clinical phenotype.
ERT was sometimes initiated at locations other than at
the investigative sites and dosing was not uniform. For
the entire patient cohort, the mean initial dose of ap-
proximately 45 units/kg/Q2W is very close to that re-
ported by ICGG for North America and globally (ICGG
2014 annual report). The proportion of patients in
whom ERT was started at ≤15 units/kg/Q2W (12.1 %)
is also similar to the global and North American ICGG
populations. In many parts of the world, limited health
care resources mandate the initial use of lower ERT
doses with an option to increase the dose should the
patient response be suboptimal. With the exception of
Toronto, Canada, there were no such dose limitations at
the North American study sites. In 2005, the ICCG US
Regional Coordinators recommended that “the initial
ERT dose should be determined in the context of the
existing severity of disease and the likelihood for contin-
ued, progressive or new onset complications…. Lowerrisk adults may begin treatment at 30 to 45 units/kg
every 2 weeks” [33]. Although many of our study pa-
tients began treatment years before publication of these
guidelines, based on the baseline DS3 scores, we found
little evidence that initial dosing decisions were driven
by assessment of patient severity.
The observed serial changes in DS3 scores and transi-
tions in GD1 health states (mild, moderate, marked) fur-
ther demonstrate not only the short-term and longer-term
effectiveness of ERT for reversing and controlling com-
mon GD1 manifestations but also reveal some of its limi-
tations. In that significant improvement in DS3 scores is
largely confined to the first 5 years from inception of treat-
ment followed by a 5-20 year plateau, our findings mirror
earlier reports that are more narrowly concentrated than
the composite DS3 score on hematological and visceral re-
sponses or on changes in surrogate biomarkers such as
serum ferritin and chitotriosidase [34–37]. However, the
DS3 methodology may be insufficiently sensitive to reflect
changes in manifestations that respond relatively slowly to
ERT such as bone mineral density [38]. For example, a
clinically significant improvement in lumbar Z-score from
-2.4 to -1.1 would generate no change in the DS3 score.
Tukan et al. discuss the advantage of using absolute BMD
values rather than T or Z scores for assessing BMD re-
sponse in patients with GD1 [39]. A better alternative
might be to calculate the DS3 DEXA component using
the FRAX© 10 year fracture risk score which corrects for
geography, DEXA machinery, body mass index, gender,
race, age, smoking and alcohol intake and prior history of
fracture. However, an MCID for fracture risk is yet to be
determined [40].
Despite evidence that the magnitude and rate of quan-
titative change in individual response parameters is ERT
dose dependent [36, 41], we were unable to establish any
relationship between either initial or cumulative ERT
dose and outcomes as measured by DS3 scores. A simi-
larly unpredictable association between ERT dosing and
composite short-term outcomes has also been reported
when achievement of therapeutic goals was the study
endpoint [5, 42]. Consequently, we conclude that DS3
scoring will not contribute to resolving the conundrum
of ERT dosing, which, because of complex individual
variation, socioeconomic considerations and insufficient
knowledge of long-term outcomes, likely will remain
empirical rather than formulaic for the foreseeable fu-
ture [39, 42].
The likelihood of experiencing improved DS3 scores
with ERT was not affected by baseline DS3 severity,
genotype (see also [42, 43]) and minimally, if at all, by
the length of time between GD1 diagnosis and initiation
of treatment. As previously shown with regard to vis-
ceral disease [44], the greatest improvements in total
DS3 score and the majority of clinically important
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when markedly affected. Nevertheless, the majority of
these individuals and about one third of the patients who
were moderately affected at baseline continued to have evi-
dence of residual disease of at least moderate severity after
5 years of treatment up to 15-20 years. This finding is con-
sistent with other literature showing that after 4 years of
ERT at variable doses, splenomegaly 8-fold or greater per-
sists in 20-40 % of ERT treated patients, thrombocytopenia
in non-splenectomized patients in 20-30 %, bone pain in
30-40 % and osteopenia in 30 % or higher depending on
patient age [5, 6, 42, 45]. After 10 years on imiglucerase,
41 of 93 patients with moderate or severe splenomegaly at
baseline still had spleen volumes 5-15 times normal, and
15 of 84 patients with moderate or marked pre-treatment
hepatomegaly continued to have liver volumes 1.25-2.5
times normal. In 38 %, the platelet count was less than
120,000/μL and 30 % had continuing bone pain [35]. In
a recent report from the Netherlands, of 28 non-
splenectomized GD1 patients without bone complica-
tions but with other signs and symptoms sufficient to
justify initiation of ERT, 25 % did not achieve “recov-
ery” (roughly equivalent to DS3 mild severity) through
10 years [29]. The prognostic importance of residual
laboratory and imaging abnormalities relative to patient-
reported health assessments and with respect to long-
term outcomes such as GD1-associated Parkinsonism and
malignancies in treated GD1 patients is still undetermined
[46] and will be a focus of continued prospective evalu-
ation in our study patients.
New AVN and lytic lesions in previously unaffected sites
in ERT-treated patients are another manifestation of incom-
plete response that may be mechanistically different from
the persistent disease manifestations discussed above. Re-
sidual hepatosplenomegaly, hypersplenic thrombocytopenia
and bone pain are likely indications of irreversible end-
organ damage (infarction, fibrosis, osteoarthritis) rather
than of treatment resistance. Fractures may have complex
etiologies not necessarily related to GD1. Among the pa-
tients with marked baseline disease, it is not surprising that
nearly half suffered new AVN or lytic lesions while on ERT
given multiple risk factors including high prevalence of
splenectomy, frequent history of pre-treatment bone events
and long interval between diagnosis and treatment [24]. On
the other hand, the observation that 12 of 75 (16 %)
patients with baseline disease scored as moderate or
mild, had AVN or lytic lesions despite continued treat-
ment is more novel. Although delayed start of ERT
may have been a contributory factor in 8 patients, only
one of 12 had a history of splenectomy and pre-
treatment bone events occurred in only 2 of 12. The
inability of ERT to completely prevent bone complica-
tions even in patients with mild phenotypes may rep-
resent a therapeutic class limitation and a justificationfor research and development of new pharmacologic
treatments for GD.Conclusions
DS3 is an effective tool for assessing pre-treatment disease
burden in GD1 and for monitoring response to therapy. It
is consistent with indirect indicators of GD1 severity such
as genotype and early age of diagnosis and symptom onset.
ERT is associated with clinically important improvement
in DS3 scores in patients with high severity scores. Never-
theless, even with sustained improvement in DS3 scores,
GD1 patients on ERT, especially those with splenectomy
and pre-treatment bone pathology are at continual risk for
emerging major bone complications. The likelihood of
ERT-emergent bone complications is only partly predicted
by either initial or serial DS3 scores and the prognostic
value of DS3 scoring for late-onset complications of GD1
such as Parkinsonism, peripheral neuropathy and GD1-
associated malignancies remains to be determined. DS3
scoring also needs to be correlated with patient-reported
outcomes and used in conjunction with validated GD1-
specific patient reporting tools when such instruments be-
come available.
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